Synonyms: BMS-477118 | Onglyza®
saxagliptin is an approved drug (EMA & FDA (2009))
Compound class:
Synthetic organic
Comment: The USAN refers to the monohydrate. Note that marketed formulations may contain saxagliptin hydrochloride PubChem CID 49800073.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: saxagliptin |
|
No information available. |
Summary of Clinical Use ![]() |
Used in the treatment of type 2 diabetes. Kombiglyze XR®, is an extended release, fixed-dose formulation containing saxagliptin and the antidiabetic drug metformin HCl, used to provide more stable glucose levels in patients with type 2 diabetes. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |